Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.

Cannabis Science President and CEO Dr. Robert Melamede, PhD., commented, "Obviously, this study gives further support to our plans to work within the multi-billion dollar market of chronic neuropathic pain. As Dr. Ware said at the beginning of the CMAJ article, cannabis sativa has been used to treat pain since the third millennium BC, so it is all the more outrageous that it has taken so long for such a study to be done, and it could only be used by patients who did not respond to anything else. Why do they have to suffer so much to prove what almost all medical marijuana users already know?"

McGill's study is the first double-blind, placebo-controlled trial conducted with outpatients who were allowed to smoke marijuana in their own homes. Participants were divided into four groups and randomly assigned marijuana containing four levels of tetrahydrocannabinol (THC), the active ingredient: at 9.4 per cent, 6.0 per cent, 2.5 per cent, and zero THC. The study was led by anesthesiologist Mark Ware, director of clinical research at Montreal's Alan Edwards Pain Management Unit at the McGill University Health Centre. It was published in the Canadian Medical Association Journal. Please see:>

Richard Cowan, Cannabis Science CFO, added, "This study demonstrates the importance of our licensing agreement with the RockBrook dispensary of Denver which we announced on August 18^th, which gives us the immediate ability to test our formulations with humans to help determine exactly what doses and strains work best for patients as we prepare to enter clinical trials."
See
http://cannabisscience.com/news-a-media/press-releases/200-cbis-signs-first-licensing-agreement-with-rockbrook.html